首付款及里程碑款总金额最高至1.1亿美元，其中包括850万美元首付款、累计不超过1.015亿美元里程碑 付款，以及净销售额的两位数百分比作为收入分成。 近日，百奥泰发布公告称，公司收到Gedeon Richter Plc.（吉瑞医药）一次性支付的250万美元里程碑付 款。 截至本公告披露日，BAT2206（乌司奴单抗）注射液已获美国食品药品监督管理局和欧洲药品管理局批 准上市，并已向国家药品监督管理局提交上市申请，目前正在评审中。 2024年10月8日，公司与吉瑞医药就 BAT2206注射液签署授权许可及生产、供货和商业化协议，将公司 的BAT2206注射液在欧盟、英国以及其他多个国家市场的独占的产品商业化权益有偿许可给吉瑞医药。 （百奥泰公告） (编辑：杨燕 林辰) ...

北京商报讯（记者 王寅浩 宋雨盈）1月9日，百奥泰发布公告称，公司于2021年8月27日与Hikma Pharmaceuticals USA Inc.（以下简称"Hikma"）签署授权许可与商业化协议，将BAT2206（乌司奴单 抗）注射液在美国市场的独占的产品商业化权益有偿许可给Hikma。根据协议约定，百奥泰于近日收到 由Hikma支付的1000万美元里程碑付款。 根据公告，BAT2206（乌司奴单抗）注射液已获美国食品药品监督管理局和欧洲药品管理局批准上市， 美国注册商品名为STARJEMZA®，欧洲注册商品名为Usymro®；已向国家药品监督管理局提交上市申 请，目前正在评审中。 ...

截至本公告披露日，BAT2206（乌司奴单抗）注射液已获美国食品药品监督管理局（FDA）和欧洲药品 管理局（EMA）批准上市，美国注册商品名为STARJEMZA®，欧洲注册商品名为 Usymro® ； 已向国 家药品监督管理局（NMPA）提交上市申请，目前正在评审中。 格隆汇1月9日丨百奥泰(688177.SH)公布，根据协议约定，百奥泰于近日收到由 Hikma 支付的1,000 万美 元里程碑付款（实际到账金额须扣除银行手续费）。该笔款项的到账，进一步充盈了公司的现金储备， 也为公司后续管线研发和国际化战略的推进提供助力。 ...

格隆汇1月9日丨百奥泰(688177.SH)公布，根据协议约定，百奥泰于近日收到由 Hikma 支付的1,000 万美 元里程碑付款（实际到账金额须扣除银行手续费）。该笔款项的到账，进一步充盈了公司的现金储备， 也为公司后续管线研发和国际化战略的推进提供助力。 截至本公告披露日，BAT2206（乌司奴单抗）注射液已获美国食品药品监督管理局（FDA）和欧洲药品 管理局（EMA）批准上市，美国注册商品名为STARJEMZA®，欧洲注册商品名为 Usymro® ； 已向国 家药品监督管理局（NMPA）提交上市申请，目前正在评审中。 ...

百奥泰1月9日公告，公司于2021年8月27日与Hikma Pharmaceuticals USA Inc.签署授权许可与商业化协 议，将BAT2206（乌司奴单抗）注射液在美国市场的独占产品商业化权益有偿许可给Hikma。根据协 议，百奥泰于近日收到Hikma支付的1000万美元里程碑付款。该笔款项将进一步充盈公司现金储备，为 后续管线研发和国际化战略推进提供助力。BAT2206注射液已获美国FDA和欧洲EMA批准上市，并向 国家药品监督管理局提交上市申请，目前正在评审中。 ...

Core Viewpoint - Baiotai has received FDA approval for BAT2206 (Ustinumab) injection, indicating a significant milestone for the company in the biopharmaceutical sector [1] Group 1: Product Approval - The FDA has approved BAT2206 (Ustinumab) injection, marketed in the U.S. as STARJEMZA [1] - The drug is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to severe active Crohn's disease, and moderate to severe active ulcerative colitis in both adults and children [1] Group 2: Commercialization Efforts - Baiotai is actively pursuing the commercialization of BAT2206 in multiple global regions [1] - The company has submitted marketing authorization applications to the NMPA in China and the EMA in Europe [1]

Core Insights - The article emphasizes the global expansion strategy of companies listed on the Sci-Tech Innovation Board, highlighting their commitment to innovation and open collaboration in the face of globalization challenges [1][7]. Group 1: Overseas Revenue Growth - In 2024, nearly 80% of Sci-Tech Innovation Board companies achieved overseas sales, with total overseas revenue reaching 430.36 billion yuan, accounting for 30% of the board's total operating income [2]. - The overseas revenue grew by 6.1% year-on-year, outpacing the overall revenue growth of the board, indicating a successful strategy to tap into international markets [2]. - Approximately 40% of companies reported a year-on-year increase in overseas revenue that exceeded their overall revenue growth, with 173 companies seeing overseas revenue growth of over 30% [2]. Group 2: Market Penetration and Product Reach - 63 companies exported products to over 50 countries, with 25 companies achieving sales in more than 100 countries [2]. - Notable examples include Kingsoft Office, which serves over 220 countries with 630 million monthly active devices, and BeiGene, whose drug has been approved in 45 markets [2]. Group 3: Competitive Positioning and Innovation - 37 companies ranked first globally in terms of shipment volume, market share, and sales in their respective fields, indicating strong market penetration [3]. - Companies like Shanghai United Imaging Healthcare have established a significant presence in over 13,000 medical institutions globally, while LalaPlus has seen a dramatic increase in overseas revenue from 2.845 million yuan in 2023 to 72.252 million yuan in 2024 [3]. Group 4: Mergers and Acquisitions - Since the introduction of the "Sci-Tech Innovation Board Eight Articles" in June 2024, 14 cross-border acquisition transactions have been initiated by listed companies [3]. - Notable acquisitions include Suzhou MicroPort's purchase of a 51% stake in Creo Medical and Suzhou Haocen's acquisition of CadLine, enhancing their international market reach [3]. Group 5: High Margin Products and Intellectual Property - The median gross margin for overseas sales of Sci-Tech Innovation Board companies reached 40.8%, surpassing the overall gross margin of the board [4]. - Companies are leveraging patented technologies for international expansion, with 10 innovative drug companies licensing their products to foreign firms [4][5]. Group 6: Global Value Chain Reconstruction - Companies are focusing on the upstream of the value chain, redefining international competition through technological innovation [4]. - 58 companies have taken the lead in setting international standards in their fields, enhancing their influence within the industry [5][6]. Group 7: Localized Production and Employment - 110 companies have established production capacities in 37 countries, contributing to local economic development [7]. - Companies like Transsion Holdings have set up factories in various countries, creating significant employment opportunities [7]. Group 8: Contribution to Global Initiatives - Several companies are actively participating in the Belt and Road Initiative, promoting advanced manufacturing and public health solutions in various countries [8]. - Examples include SANY Heavy Industry's factory in Indonesia and Haier Biomedical's solar-powered cold storage solution in Nigeria [8].